Alexandra Traverse-Glehen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexandra Traverse-Glehen has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- Camille Laurent
Laboratoire d'Excellence TOUCAN, Centre de Recherches en Cancérologie de Toulouse INSERM U1037, Institut Universitaire Cancer‐Oncopole, CHU Toulouse Toulouse France
9 shared publications - Marie-Cécile Parrens
Department of Hematology, Centre Hospitalier Universitaire Bordeaux, Bordeaux, France
9 shared publications - Arnaud Jaccard
Department of Hematology and Cellular Therapy University Hospital of Limoges Limoges France
8 shared publications - Emmanuel Bachy
Department of Hematology, Lyon-Sud Hospital Center, Pierre-Bénite, France
8 shared publications - Gandhi Damaj
Caen University Hospital, Caen, France
8 shared publications - Ai Okada
National Cancer Center Research Institute
7 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
Supplemental Figure 1. Association between genetic alterations and methylation patterns Supplemental Figure 2. Epitypes characteristics and their relation to other lymphomas. Supplemental Figure 3. Comparison of epitype characteristics in relation to EBV status. Supplemental Figure 4. Validation of epitypes using Nanopore sequencing data. Supplemental Figure 5. Selected characteristics of BL epitypes and relative aSHM frequencies in EBV-positive BL. Supplemental Figure 6. GSEA plots for SignatureDB pathways determined to be significantly different between BL epitypes. Supplemental Figure 7. The Cox proportional hazards models accounting for both BL epitype and TP53 mutation status in adult BLs.
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
Supplemental Figure 1. Association between genetic alterations and methylation patterns Supplemental Figure 2. Epitypes characteristics and their relation to other lymphomas. Supplemental Figure 3. Comparison of epitype characteristics in relation to EBV status. Supplemental Figure 4. Validation of epitypes using Nanopore sequencing data. Supplemental Figure 5. Selected characteristics of BL epitypes and relative aSHM frequencies in EBV-positive BL. Supplemental Figure 6. GSEA plots for SignatureDB pathways determined to be significantly different between BL epitypes. Supplemental Figure 7. The Cox proportional hazards models accounting for both BL epitype and TP53 mutation status in adult BLs.
- Open Access
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
S1. DMRs EBVpos vs CB S2. DMRs EBVneg vs CB S3. Shared DMRs EBV S4. DMRs EBV status S5. Methylation gene corrs EB S6. GO pathways enrichment S7. LPS selected probes S8. Epitype assignment S9. DMRs eptiype S10. DMR gene corrs epitype S11. JASPAR TF results epitype S12. JASPAR TF results EBV S13. aSHM epitype S14. DEG epitpye S15. SignatureDB pathways enrichment
- 1 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
S1. DMRs EBVpos vs CB S2. DMRs EBVneg vs CB S3. Shared DMRs EBV S4. DMRs EBV status S5. Methylation gene corrs EB S6. GO pathways enrichment S7. LPS selected probes S8. Epitype assignment S9. DMRs eptiype S10. DMR gene corrs epitype S11. JASPAR TF results epitype S12. JASPAR TF results EBV S13. aSHM epitype S14. DEG epitpye S15. SignatureDB pathways enrichment
- Open Access
- 8 May 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (4) , 325-342
DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
The genetic subtypes of Burkitt lymphoma have been defined, but the role of epigenetics remains to be comprehensively characterized. We searched genomic DNA from 218 patients across four continents for recurrent DNA methylation patterns and their associations with clinical and molecular features. We identified DNA methylation patterns that were not fully explained by the Epstein–Barr virus status or mutation status, leading to two epitypes described here as HypoBL and HyperBL. Each is characterized by distinct genomic and clinical features including global methylation, mutation burden, aberrant somatic hypermutation, and survival outcomes. Methylation, gene expression, and mutational differences between the epitypes support a model in which each arises from a distinct cell of origin. These results, pending validation in external cohorts, point to a refined risk assessment for patients with Burkitt lymphoma who may experience inferior outcomes. Significance: Burkitt lymphoma can be divided into two epigenetic subtypes (epitypes), each carrying distinct biological, transcriptomic, genomic, and clinical features. Epitype is more strongly associated with clinical and mutational features than the Epstein–Barr virus status or genetic subtype, highlighting an important additional layer of Burkitt lymphoma pathogenesis.
- 8 May 2025
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 6 (4) , 325-342
Open AccessDNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features
The genetic subtypes of Burkitt lymphoma have been defined, but the role of epigenetics remains to be comprehensively characterized. We searched genomic DNA from 218 patients across four continents for recurrent DNA methylation patterns and their associations with clinical and molecular features. We identified DNA methylation patterns that were not fully explained by the Epstein–Barr virus status or mutation status, leading to two epitypes described here as HypoBL and HyperBL. Each is characterized by distinct genomic and clinical features including global methylation, mutation burden, aberrant somatic hypermutation, and survival outcomes. Methylation, gene expression, and mutational differences between the epitypes support a model in which each arises from a distinct cell of origin. These results, pending validation in external cohorts, point to a refined risk assessment for patients with Burkitt lymphoma who may experience inferior outcomes. Significance: Burkitt lymphoma can be divided into two epigenetic subtypes (epitypes), each carrying distinct biological, transcriptomic, genomic, and clinical features. Epitype is more strongly associated with clinical and mutational features than the Epstein–Barr virus status or genetic subtype, highlighting an important additional layer of Burkitt lymphoma pathogenesis.
- Open Access
- 15 April 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (3) , e70027
Netrin‐1 and B‐cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives
Netrin‐1 and B‐cell maturation antigen (BCMA) are currently being evaluated as therapeutic targets in oncology. However, studies investigating their expression in mature human lymphoid malignancies are sparse. This study aimed to investigate the expression of BCMA and Netrin‐1 in a large cohort of lymphomas to determine their potential role as biomarkers or therapeutic targets. BCMA and Netrin‐1 expression was investigated comprehensively using immunohistochemistry in a cohort that included 261 B‐cell lymphomas, 45 T‐cell lymphomas, and 55 classical Hodgkin lymphomas. Netrin‐1 displayed a cytoplasmic staining pattern in plasmablastic lymphomas (27/28, 96%) and classical Hodgkin lymphomas (8/55, 15%). BCMA displayed cytoplasmic staining in most plasmablastic lymphomas (17/20, 85%). Among mature B‐cell lymphomas, Netrin‐1 and BCMA displayed sensitive (96% and 85%, respectively) and specific (100% and 95%, respectively) staining in plasmablastic lymphomas. These results suggest that these proteins may help pathologists in complex diagnoses and reinforce the interest in developing clinical trials assessing Netrin‐1 or BCMA‐targeted therapies in plasmablastic lymphoma and classical Hodgkin lymphomas, for which our therapeutic arsenal is weak.
- 15 April 2025
- Published by Wiley in The Journal of Pathology: Clinical Research
- Vol. 11 (3) , e70027
Open AccessNetrin‐1 and B‐cell maturation antigen expression in a large cohort of 361 lymphomas: sensitive and specific staining in plasmablastic lymphomas, and therapeutic perspectives
Netrin‐1 and B‐cell maturation antigen (BCMA) are currently being evaluated as therapeutic targets in oncology. However, studies investigating their expression in mature human lymphoid malignancies are sparse. This study aimed to investigate the expression of BCMA and Netrin‐1 in a large cohort of lymphomas to determine their potential role as biomarkers or therapeutic targets. BCMA and Netrin‐1 expression was investigated comprehensively using immunohistochemistry in a cohort that included 261 B‐cell lymphomas, 45 T‐cell lymphomas, and 55 classical Hodgkin lymphomas. Netrin‐1 displayed a cytoplasmic staining pattern in plasmablastic lymphomas (27/28, 96%) and classical Hodgkin lymphomas (8/55, 15%). BCMA displayed cytoplasmic staining in most plasmablastic lymphomas (17/20, 85%). Among mature B‐cell lymphomas, Netrin‐1 and BCMA displayed sensitive (96% and 85%, respectively) and specific (100% and 95%, respectively) staining in plasmablastic lymphomas. These results suggest that these proteins may help pathologists in complex diagnoses and reinforce the interest in developing clinical trials assessing Netrin‐1 or BCMA‐targeted therapies in plasmablastic lymphoma and classical Hodgkin lymphomas, for which our therapeutic arsenal is weak.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends